93 filings
6-K
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
25 Apr 24
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
8:03am
6-K
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
16 Apr 24
Virax Biolabs Group Limited to Participate at ESCMID Global 2024
7:34am
6-K
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
15 Mar 24
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
4:32pm
6-K
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
6-K
1jweetek0dunof cn
12 Jan 24
Current report (foreign)
7:43am
6-K
a3cm8413 mh
21 Dec 23
Current report (foreign)
7:34am
424B3
pyv2xkreo vq92cwq4e
20 Dec 23
Prospectus supplement
4:12pm
6-K
7rag8vg iktvgd
20 Dec 23
Current report (foreign)
4:06pm
424B3
ppo31
20 Dec 23
Prospectus supplement
4:03pm
6-K
pbvxtcmhsjt umh79hr8
18 Dec 23
Virax Biolabs’ CEO James Foster Issues Letter to Shareholders
7:37am
EFFECT
8evez r888s
18 Dec 23
Notice of effectiveness
12:15am
6-K
ksu1v
14 Dec 23
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
7:43am
CORRESP
ly0kparals cedk7o7
13 Dec 23
Correspondence with SEC
12:00am
UPLOAD
3sj wyhcy4
12 Dec 23
Letter from SEC
12:00am
6-K
slhoan8
8 Dec 23
Current report (foreign)
6:03am
F-3
7ubaf2
5 Dec 23
Shelf registration (foreign)
4:06pm
6-K
6xctf7vluy58 12ny7
8 Nov 23
Current report (foreign)
4:11pm
6-K
vwhbmj9otfwn y386
31 Oct 23
Current report (foreign)
4:38pm
D
v87lv3qq29uoyipk69u
17 Oct 23
$2.15 mm in equity / options / securities to be acquired, sold $2.15 mm, 1 investor
4:05pm